Roche Inks $549M Deal To License 'Superbug' Antibiotic

Law360, New York (November 4, 2013, 2:43 PM EST) -- Biotech giant Roche will pay up to 500 million Swiss francs ($549 million) to Polyphor Ltd. for an exclusive worldwide license agreement to develop and market its drug that targets an antibiotic-resistant "superbug" bacteria often found in hospitals, according to a statement.

Roche, under the deal terms, will make an initial payment of 35 million Swiss francs followed by payments based on development, regulatory and commercial milestones of the POL7080 antibiotic, according to a statement. Polyphor will also receive tiered royalties on product sales and will...
To view the full article, register now.